![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 5
2018
Stähler, M.; Motzer, R. J.; George, D. J.; Pandha, H. S.; Donskov, F.; Escudier, B.; Pantuck, A. J.; Patel, A.; DeAnnuntis, L.; Bhattacharyya, H.; Ramaswamy, K.; Zanotti, G.; Lin, X.; Lechuga, M.; Serfass, L.; Paty, J. und Ravaud, A.
(2018):
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.
In: Annals of Oncology, Bd. 29, Nr. 10: S. 2098-2104
2017
Powles, T.; McDermott, D. F.; Rini, B.; Motzer, R. J.; Atkins, M. B.; Fong, L.; Joseph, R. W.; Pal, S. K.; Ravaud, A.; Bracarda, S.; Suarez Rodriguez, C.; Maio, M.; Gore, M.; Grünwald, V.; Stähler, M.; Qiu, J.; Thobhani, A.; Huseni, M.; Schiff, C. und Escudier, B.
(2017):
IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC).
In: Annals of Oncology, Bd. 28
Stähler, M.; Motzer, R. J.; George, D. J.; Pandha, H. S.; Donskov, F.; Escudier, B.; Kliment, J.; Pantuck, A. J.; Patel, A.; Deannuntis, L.; Bhattacharyya, H.; Lin, X.; Lechuga, M.; Serfass, L.; Patard, J.-J. und Ravaud, A.
(2017):
Adjuvant sunitinib (SU) in patients (pts) with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial.
In: Annals of Oncology, Bd. 28
2016
Ravaud, A.; Motzer, R. J.; Pandha, H. S.; George, D. J.; Pantuck, A. J.; Patel, A.; Chang, Y.-H.; Escudier, B.; Donskov, F.; Magheli, A.; Carteni, G.; Laguerre, B.; Tomczak, P.; Breza, J.; Gerletti, P.; Lechuga, M.; Lin, X.; Martini, J.-F.; Ramaswamy, K.; Casey, M.; Staehler, M. und Patard, J.-J.
(2016):
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
In: New England Journal of Medicine, Bd. 375, Nr. 23: S. 2246-2254
Ravaud, A.; Motzer, R. J.; Pandha, H. S.; Staehler, M.; George, D.; Pantuck, A. J.; Patel, A.; Chang, Y.-H.; Escudier, B.; Donskov, F.; Magheli, A.; Carteni, G.; Laguerre, B.; Tomczak, P.; Breza, J.; Gerletti, P.; Lin, X.; Lechuga, M.; Martini, J.-F. und Patard, J.-J.
(2016):
Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC).
In: Annals of Oncology, Bd. 27